A61K 31/675
Having nitrogen as a ring hetero atom
Official title: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K31/675 (Having nitrogen as a ring hetero atom) appears on 3,008 US grants and 5,697 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,008
- Published applications
- 5,697
- Assignees
- 2,150
- Inventors
- 10,369
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 5 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 3 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 3 | 0 |
| 1988 | 7 | 0 |
| 1989 | 7 | 0 |
| 1990 | 11 | 0 |
| 1991 | 13 | 0 |
| 1992 | 12 | 0 |
| 1993 | 13 | 0 |
| 1994 | 11 | 0 |
| 1995 | 11 | 0 |
| 1996 | 19 | 0 |
| 1997 | 23 | 0 |
| 1998 | 25 | 0 |
| 1999 | 44 | 0 |
| 2000 | 52 | 0 |
| 2001 | 42 | 18 |
| 2002 | 41 | 44 |
| 2003 | 44 | 87 |
| 2004 | 37 | 114 |
| 2005 | 24 | 123 |
| 2006 | 39 | 103 |
| 2007 | 29 | 117 |
| 2008 | 46 | 91 |
| 2009 | 34 | 109 |
| 2010 | 45 | 120 |
| 2011 | 51 | 121 |
| 2012 | 59 | 137 |
| 2013 | 93 | 185 |
| 2014 | 133 | 272 |
| 2015 | 162 | 314 |
| 2016 | 161 | 316 |
| 2017 | 211 | 322 |
| 2018 | 220 | 331 |
| 2019 | 192 | 298 |
| 2020 | 149 | 274 |
| 2021 | 157 | 372 |
| 2022 | 179 | 382 |
| 2023 | 141 | 415 |
| 2024 | 157 | 385 |
| 2025 | 172 | 369 |
| 2026 | 121 | 278 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin6 Oct 2026US 12,751,960 B2Compass Pathfinder Limited
- TLR7/8 antagonists and uses thereof22 Sep 2026US 12,740,978 B2Merck Patent GmbH
- Polypeptide that specifically binding to CD123 protein, polypeptide complex, co-delivery system and preparation method and use thereof22 Sep 2026US 12,742,016 B2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
- Treatment of immunosuppressed subjects15 Sep 2026US 12,734,216 B2NantCell, Inc.
- Cell therapeutic agent for cancer treatment and combination therapy with same15 Sep 2026US 12,735,680 B2Cell & Brain Co., Ltd
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Psilocybin compositions8 Oct 2026US 2026/0306474 A1Turtle Bear Holdings, LLC
- Substituted pyrimidinedione compounds, compositions, and uses thereof8 Oct 2026US 2026/0308184 A1Lakewood Amedex, Inc.
- Stat degraders and uses thereof8 Oct 2026US 2026/0308185 A1Recludix Pharma, Inc.
- Stat degraders and uses thereof8 Oct 2026US 2026/0308186 A1Recludix Pharma, Inc.
Most cited
By later US patents
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Methods for treating diabetic neuropathy258US 7,030,146 B2Kansas University Medical Center · 2006
- Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody199US 6,455,043 B1IDEC Pharmaceuticals Corporation · 2002
- N.sup.6 - substituted nucleotide analagues and their use194US 5,977,061 AInstitute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic · 1999
- Adoptive cell therapy with young T cells191US 8,383,099 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2013